ABOS
Acumen Pharmaceuticals Inc
Biotechnology
Acumen Pharmaceuticals Inc (ABOS) Stock News
The latest ABOS headlines and market coverage — 1 recent story, updated throughout the day.
- The Motley Fool·
Acumen Pharmaceuticals (ABOS) Q3 2026 Earnings Call Transcript
Acumen Pharmaceuticals reported Q3 2026 results with a net loss of $25.4 million and cash reserves of $78.6 million expected to support operations into early 2027. The company is preparing for November 2026 topline results from its Phase 2 ALTITUDE-AD trial testing sabirnetug for early Alzheimer's disease, with 542 participants enrolled. Management expects a 30% slowing of cognitive decline on the iADRS scale as the clinical success benchmark and anticipates low double-digit ARIA-E safety rates. The company is also advancing its Enhanced Brain Delivery program toward an IND filing in mid-2027.